Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7299
    -0.0021 (-0.29%)
     

  • CRUDE OIL

    82.83
    -0.53 (-0.64%)
     

  • Bitcoin CAD

    87,873.53
    -3,057.27 (-3.36%)
     

  • CMC Crypto 200

    1,385.35
    -38.75 (-2.72%)
     

  • GOLD FUTURES

    2,328.80
    -13.30 (-0.57%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,511.25
    -95.50 (-0.54%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6820
    -0.0016 (-0.23%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

EBS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Emergent Biosolutions Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - May 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Emergent Biosolutions Inc. (NYSE: EBS) alleging that the Company violated federal securities laws.

Class Period: July 6, 2020 and March 31, 2021
Lead Plaintiff Deadline: June 18, 2021

Learn more about your recoverable losses in EBS:
http://www.kleinstocklaw.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?id=15890&from=5

The filed complaint alleges that Emergent Biosolutions Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.

ADVERTISEMENT

Shareholders have until June 18, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the EBS lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/84173